Martin Sattler

Martin Sattler

UNVERIFIED PROFILE

Are you Martin Sattler?   Register this Author

Register author
Martin Sattler

Martin Sattler

Publications by authors named "Martin Sattler"

Are you Martin Sattler?   Register this Author

85Publications

1820Reads

9Profile Views

Rationally derived drug combinations with the novel Mcl-1 inhibitor EU-5346 in breast cancer.

Breast Cancer Res Treat 2019 Feb 29;173(3):585-596. Epub 2018 Oct 29.

Department of Medical Oncology, National Center for Tumor Diseases (NCT), University of Heidelberg, Heidelberg, Germany.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10549-018-5022-5
Publisher Site
http://dx.doi.org/10.1007/s10549-018-5022-5DOI Listing
February 2019

Modeling small cell lung cancer (SCLC) biology through deterministic and stochastic mathematical models.

Oncotarget 2018 May 25;9(40):26226-26242. Epub 2018 May 25.

Dana-Farber Cancer Institute, Department of Medical Oncology, Boston 02215, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.25360DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5995226PMC
May 2018

Midostaurin, a Natural Product-Derived Kinase Inhibitor Recently Approved for the Treatment of Hematological Malignancies.

Biochemistry 2018 02 30;57(5):477-478. Epub 2017 Nov 30.

Department of Medical Oncology, Dana Farber Cancer Institute , Boston, Massachusetts 02215, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/acs.biochem.7b01126DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6295915PMC
February 2018

MET in the Driver's Seat: Exon 14 Skipping Mutations as Actionable Targets in Lung Cancer.

J Thorac Oncol 2016 09;11(9):1381-3

Department of Medical Oncology and Therapeutics Research, City of Hope, Duarte, California. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2016.07.003DOI Listing
September 2016

Inhibition of Propionibacterium acnes associated biofilm formation by Decanediol.

J Dermatol Sci 2016 Aug 10;83(2):159-61. Epub 2016 May 10.

Beiersdorf AG, Research and Development, Hamburg, Germany. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jdermsci.2016.05.003DOI Listing
August 2016

Mcl-1 confers protection of Her2-positive breast cancer cells to hypoxia: therapeutic implications.

Breast Cancer Res 2016 Feb 26;18(1):26. Epub 2016 Feb 26.

Department of Medical Oncology, National Center for Tumor Diseases (NCT), University of Heidelberg, Im Neuenheimer Feld #460, Heidelberg, 69120, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-016-0686-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4769490PMC
February 2016

Rescue of Hippo coactivator YAP1 triggers DNA damage-induced apoptosis in hematological cancers.

Nat Med 2014 Jun 11;20(6):599-606. Epub 2014 May 11.

1] Functional Genomics of Cancer Unit, Division of Molecular Oncology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Scientific Institute, Milan, Italy. [2] Università Vita-Salute San Raffaele, Milan, Italy. [3] MAGIC (Microenvironment and Genes in Cancers of the blood) Interdivisional Research Program, IRCCS San Raffaele Scientific Institute, Milan, Italy. [4].

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nm.3562DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4057660PMC
June 2014

Targeting Mcl-1 for multiple myeloma (MM) therapy: drug-induced generation of Mcl-1 fragment Mcl-1(128-350) triggers MM cell death via c-Jun upregulation.

Cancer Lett 2014 Feb 8;343(2):286-94. Epub 2013 Oct 8.

Medical Oncology, National Center for Tumor Diseases (NCT), University of Heidelberg and German Cancer Research Center (DKFZ), Heidelberg, Germany. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.canlet.2013.09.042DOI Listing
February 2014

Structure of a pseudokinase-domain switch that controls oncogenic activation of Jak kinases.

Nat Struct Mol Biol 2013 Oct 8;20(10):1221-3. Epub 2013 Sep 8.

1] Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts, USA. [2] Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nsmb.2673DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3863620PMC
October 2013

A new hope for precision medicine.

Sci Transl Med 2013 Oct;5(208):208fs38

Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL 60637, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1126/scitranslmed.3007622DOI Listing
October 2013

A tissue-engineered human dermal construct utilizing fibroblasts and transforming growth factor β1 to promote elastogenesis.

Biotechnol J 2013 Mar;8(3):317-26

Research and Development, Beiersdorf AG, Unnastrasse, Hamburg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/biot.201200209DOI Listing
March 2013

Impact of collagen crosslinking on the second harmonic generation signal and the fluorescence lifetime of collagen autofluorescence.

Skin Res Technol 2012 May 12;18(2):168-79. Epub 2011 May 12.

Research & Development, Beiersdorf AG, Hamburg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1600-0846.2011.00549.xDOI Listing
May 2012

Targeting JAK2 in the therapy of myeloproliferative neoplasms.

Expert Opin Ther Targets 2012 Mar 17;16(3):313-24. Epub 2012 Feb 17.

Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, MA 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14728222.2012.662956DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4051134PMC
March 2012

Aconitase regulation of erythropoiesis correlates with a novel licensing function in erythropoietin-induced ERK signaling.

PLoS One 2011 22;6(8):e23850. Epub 2011 Aug 22.

Department of Pathology, University of Virginia School of Medicine, Charlottesville, Virginia, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0023850PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3161794PMC
February 2012

The role of the c-Met pathway in lung cancer and the potential for targeted therapy.

Ther Adv Med Oncol 2011 Jul;3(4):171-84

Department of Medical Oncology, Dana-Farber Cancer Institute, and Brigham and Women's Hospital, Harvard Medical School, 450 Brookline Avenue, Boston, MA 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1758834011408636DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3150066PMC
July 2011

Mutant Cbl proteins as oncogenic drivers in myeloproliferative disorders.

Oncotarget 2011 Mar;2(3):245-50

Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3134300PMC
http://dx.doi.org/10.18632/oncotarget.233DOI Listing
March 2011

JAK2 gets histone H3 rolling.

Cancer Cell 2009 Nov;16(5):365-6

Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccr.2009.10.009DOI Listing
November 2009

BCR-ABL promotes the frequency of mutagenic single-strand annealing DNA repair.

Blood 2009 Aug 1;114(9):1813-9. Epub 2009 Jul 1.

Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2008-07-172148DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2738569PMC
August 2009

The MET axis as a therapeutic target.

Update Cancer Ther 2009 Apr;3(3):109-118

Department of Medical Oncology, Dana-Farber Cancer Institute 44 Binney Street, Boston, MA 02115.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.uct.2009.01.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2847295PMC
April 2009

Cell cycle regulation by oncogenic tyrosine kinases in myeloid neoplasias: from molecular redox mechanisms to health implications.

Antioxid Redox Signal 2008 Oct;10(10):1813-48

Department of Medical Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/ars.2008.2071DOI Listing
October 2008

EGFR-targeted therapeutics: focus on SCCHN and NSCLC.

ScientificWorldJournal 2008 Sep 21;8:909-19. Epub 2008 Sep 21.

Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1100/tsw.2008.117DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5848684PMC
September 2008

Secondary Collapse of an Expandable Cage After Vertebral Corpectomy.

Eur J Trauma Emerg Surg 2007 Dec 11;33(6):659-61. Epub 2007 May 11.

Trauma Department, Hannover Medical School, Hannover, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00068-007-6021-0DOI Listing
December 2007

c-Met and hepatocyte growth factor: potential as novel targets in cancer therapy.

Curr Oncol Rep 2007 Mar;9(2):102-8

Department of Medicine, Pritzker School of Medicine, University of Chicago, 5841 South Maryland Avenue, Chicago, IL 60637, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-007-0005-4DOI Listing
March 2007

Activated Jak2 with the V617F point mutation promotes G1/S phase transition.

J Biol Chem 2006 Jun 21;281(26):18177-83. Epub 2006 Apr 21.

Department of Medical Oncology, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1074/jbc.M600064200DOI Listing
June 2006

Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML).

Crit Rev Oncol Hematol 2006 Feb 5;57(2):145-64. Epub 2005 Oct 5.

Department of Medical Oncology, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.critrevonc.2005.06.007DOI Listing
February 2006

Activation of the PI3K/mTOR pathway by BCR-ABL contributes to increased production of reactive oxygen species.

Blood 2005 Feb 14;105(4):1717-23. Epub 2004 Oct 14.

Department of Medical Oncology, Dana-Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2004-03-0849DOI Listing
February 2005

Caveolin-1 is required for vascular endothelial growth factor-triggered multiple myeloma cell migration and is targeted by bortezomib.

Cancer Res 2004 Oct;64(20):7500-6

Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.

View Article

Download full-text PDF

Source
http://cancerres.aacrjournals.org/lookup/doi/10.1158/0008-54
Publisher Site
http://dx.doi.org/10.1158/0008-5472.CAN-04-0124DOI Listing
October 2004

Targeting mutated tyrosine kinases in the therapy of myeloid leukaemias.

Expert Opin Ther Targets 2004 Jun;8(3):221-39

Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14728222.8.3.221DOI Listing
June 2004

Therapeutic targeting of the receptor tyrosine kinase Met.

Cancer Treat Res 2004 ;119:121-38

Department of Medical Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/1-4020-7847-1_7DOI Listing
June 2004

Critical role for hematopoietic cell kinase (Hck)-mediated phosphorylation of Gab1 and Gab2 docking proteins in interleukin 6-induced proliferation and survival of multiple myeloma cells.

J Biol Chem 2004 May 9;279(20):21658-65. Epub 2004 Mar 9.

Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1074/jbc.M305783200DOI Listing
May 2004

Targeting c-Kit mutations: basic science to novel therapies.

Leuk Res 2004 May;28 Suppl 1:S11-20

Department of Medical Oncology, Dana-Farber Cancer Institute, Department of Medicine, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S014521260300329
Publisher Site
http://dx.doi.org/10.1016/j.leukres.2003.10.004DOI Listing
May 2004

Mutated tyrosine kinases as therapeutic targets in myeloid leukemias.

Adv Exp Med Biol 2003 ;532:121-40

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-1-4615-0081-0_11DOI Listing
February 2004

c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions.

Cancer Res 2003 Oct;63(19):6272-81

Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
October 2003

Superoxide-dependent and -independent mitochondrial signaling during apoptosis in multiple myeloma cells.

Oncogene 2003 Sep;22(40):6296-300

Department of Medical Oncology, The Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/1206734
Publisher Site
http://dx.doi.org/10.1038/sj.onc.1206734DOI Listing
September 2003

A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase.

Cancer Res 2003 Sep;63(17):5462-9

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA.

View Article

Download full-text PDF

Source
September 2003

2-methoxyestradiol alters cell motility, migration, and adhesion.

Blood 2003 Jul 13;102(1):289-96. Epub 2003 Mar 13.

Department of Medical Oncology, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2002-03-0729DOI Listing
July 2003

Cell motility, adhesion, homing, and migration assays in the studies of tyrosine kinases.

Methods Mol Med 2003 ;85:87-105

Department of Medical Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1385/1-59259-380-1:87DOI Listing
June 2003

Molecular mechanisms of transformation by the BCR-ABL oncogene.

Semin Hematol 2003 Apr;40(2 Suppl 2):4-10

Department of Medical Oncology, Dana-Farber Cancer Institute, and Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/shem.2003.50034DOI Listing
April 2003

Essential role of caveolae in interleukin-6- and insulin-like growth factor I-triggered Akt-1-mediated survival of multiple myeloma cells.

J Biol Chem 2003 Feb 12;278(8):5794-801. Epub 2002 Dec 12.

Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1074/jbc.M208636200DOI Listing
February 2003

Molecular and cellular biology of small cell lung cancer.

Semin Oncol 2003 Feb;30(1):57-71

Department of Medical Oncology, Division of Thoracic Oncology Program, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/sonc.2003.50019DOI Listing
February 2003

Regulation of cellular proliferation, cytoskeletal function, and signal transduction through CXCR4 and c-Kit in small cell lung cancer cells.

Cancer Res 2002 Nov;62(21):6304-11

Department of Adult Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA.

View Article

Download full-text PDF

Source
November 2002

2-Methoxyestradiol overcomes drug resistance in multiple myeloma cells.

Blood 2002 Sep;100(6):2187-94

Department of Adult Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Boston, MA 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2002-02-0376DOI Listing
September 2002

Critical role for Gab2 in transformation by BCR/ABL.

Cancer Cell 2002 Jun;1(5):479-92

Dana-Farber Cancer Institute, Department of Adult Oncology, Harvard Medical School, 44 Binney Street, Boston, Massachusetts 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s1535-6108(02)00074-0DOI Listing
June 2002

Vascular endothelial growth factor-induced migration of multiple myeloma cells is associated with beta 1 integrin- and phosphatidylinositol 3-kinase-dependent PKC alpha activation.

J Biol Chem 2002 Mar 20;277(10):7875-81. Epub 2001 Dec 20.

Jerome Lipper Multiple Myeloma Research Center/Dana-Farber Cancer Institute and the Department of Medicine, Harvard Medical School, Boston, Massachusetts 02115, USA.

View Article

Download full-text PDF

Source
http://www.jbc.org/lookup/doi/10.1074/jbc.M109068200
Publisher Site
http://dx.doi.org/10.1074/jbc.M109068200DOI Listing
March 2002

Differential expression and signaling of CBL and CBL-B in BCR/ABL transformed cells.

Oncogene 2002 Feb;21(9):1423-33

Department of Adult Oncology, Dana-Farber Cancer Institute, 44 Binney Street, Boston, Massachusetts 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/sj.onc.1205202DOI Listing
February 2002